Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Zonegran; Czech Republic: Zonegran; Denmark: Zonegran; Estonia: Zonegran; Finland: Zonegran; France: Zonegran; Germany: Zonegran; Greece: Zonegran; Hungary: Zonegran; Ireland: Zonegran; Italy: Zonegran; Latvia: Zonegran; Lithuania: Zonegran; Luxembourg: Zonegran; Malta: Zonegran; Netherlands: Zonegran; Poland: Zonegran; Portugal: Zonegran; Romania: Zonegran; Slovakia: Zonegran; Slovenia: Zonegran; Spain: Zonegrán; Sweden: Zonegran; UK: Zonegran.

North America

USA: Zonegran, Zonisamide.

Latin America

Argentina: Kinaplase.


Japan: Excegran, Excemide.

Drug combinations


Zonisamide: C~8~H~8~N~2~O~3~S. Mw: 212.23. 1,2-Benzisoxazole-3-methanesulfonamide. CAS-68291-97-4 (1985).

Pharmacologic Category

Anticonvulsants, Miscellaneous. (ATC-Code: N03AX15).

Mechanism of action

Exact mechanism of action not known. May stabilize neuronal membranes and suppress neuronal hypersynchronization through action at sodium and calcium channels. Does not affect GABA activity.

Therapeutic use

Adjunct treatment of partial seizures in children >16 years of age and adults with epilepsy.

Pregnancy and lactiation implications

Fetal abnormalities and death reported in animals, however, there are no studies in pregnant women. Use during pregnancy and lactation only if potential benefits outweigh potential risks.

Unlabeled use

Bipolar disorder.


Hypersensitivity to zonisamide, sulfonamides, or any component of the formulation.

Warnings and precautions

Significant CNS effects (psychiatric symptoms, psychomotor slowing, fatigue, somnolence), may occur. May cause metabolic acidosis (predisposing conditions/therapies include renal disease, severe respiratory disease, diarrhea, surgery, ketogenic diet, and other medications). Pediatric patients may also be at increased risk and may have more severe metabolic acidosis. Discontinue therapy in patients who develop acute renal failure or significant sustained increase in creatinine/BUN concentration (kidney stones reported). Rare, but potentially fatal sulfonamide reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) occurred following use. Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in sulfonamide allergy contraindicated (risk of cross-reaction). Use with caution in hepatic and renal impairment. Effects with other sedative drugs or ethanol may be potentiated. Decreased sweating (oligohidrosis) and hyperthermia requiring hospitalization reported in children. Anticonvulsants should not be discontinued abruptly.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart